#COPD is currently an incurable disease that impacts millions of people in the US. Our novel inhaled therapy can be used alone or added to other COPD therapies without the need to replace another treatment. Learn more: https://bit.ly/3YqQ7Ai
Verona Pharma
Biotechnology Research
London, UK 15,558 followers
Developing life enhancing treatments for chronic respiratory diseases
About us
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in ENHANCE-1 and ENHANCE-2. We are led by a management team with an established track record in the discovery, development and commercialization of respiratory therapies. Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and Savannah in the US. For more information, please visit https://www.veronapharma.com.
- Website
-
https://www.veronapharma.com
External link for Verona Pharma
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London, UK
- Type
- Public Company
- Founded
- 2005
- Specialties
- Novel therapies for chronic respiratory diseases , COPD, CF, and Asthma
Locations
-
Primary
3 More London Riverside
London, UK SE1 2RE, GB
-
8045 Arco Corporate Drive
Suite 130
Raleigh, North Carolina 27617, US
-
33 Park of Commerce Way
Savannah, Georgia 31405, US
Employees at Verona Pharma
Updates
-
Today, we are attending #CHEST2024 in Boston, where we’re presenting additional analyses of our #Phase3 ENHANCE data for #COPD. Stop by our booth, 1059, from 10am and learn more about our abstracts here: https://bit.ly/4gDT9YN American College of Chest Physicians
-
October is #HealthyLungMonth, a time to raise awareness about #respiratory health and how to protect your lungs. At Verona, we are committed to improving the lives of patients with respiratory conditions, from #COPD to #NonCFBronchiectasis. For more information on lung health and wellness, see this helpful guide from the American Lung Association: https://bit.ly/3YJJHME
-
Come see us at the American College of Chest Physicians' CHEST Annual Meeting! Our team will be sharing further analyses from the #Phase3 ENHANCE trials in #COPD. Learn more about our #CHEST2024 abstracts here: https://bit.ly/4gDT9YN
-
Our mission at Verona Pharma is to improve the lives of those affected by the burden of chronic respiratory diseases. That’s why we’re excited and committed to helping patients through innovative therapies. Learn more about COPD here: https://bit.ly/3MePfYg
-
Verona Pharma reposted this
Verona Pharma had the honor of ringing the Nasdaq #closingbell – a celebration of the hard work, innovation, and commitment that brought us to this moment. Our thanks go to our incredible team, trusted partners, and the patients and HCPs who inspire us every day. The launch of #Ohtuvayre (ensifentrine) is just the beginning.
-
Verona Pharma had the honor of ringing the Nasdaq #closingbell – a celebration of the hard work, innovation, and commitment that brought us to this moment. Our thanks go to our incredible team, trusted partners, and the patients and HCPs who inspire us every day. The launch of #Ohtuvayre (ensifentrine) is just the beginning.
-
We’re thrilled to announce that Verona has been named a finalist for the Best New Drug award category at the 2024 Scrip Awards! The #ScripAwards brings together over 400 global leaders to honor breakthroughs across 15 categories. Being recognized in the Best New Drug category highlights the therapeutic advancement of our new treatment and its impact on improving patients’ lives. A huge thanks to our dedicated team and partners for their ongoing commitment!
-
We’re excited to announce that on September 17th, Verona Pharma will ring the Nasdaq #closingbell, to celebrate the recent launch of #Ohtuvayre (ensifentrine). We’re excited to share this moment with our team, partners, and the broader healthcare community.
-
We are on the ground in Vienna, Austria at the European Respiratory Society (ERS) Congress. Don't miss your chance to hear the results from our four oral and poster presentations, covering additional analyses from our #Phase3 ENHANCE trials in patients with #COPD. Learn more: https://bit.ly/4ggwnpp #ERSCongress